NCT01332188 - Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model | Biotech Hunter

Enrollment

101

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

June 30, 2011

Study Completion Date

October 31, 2011

Conditions

Allergic Conjunctivitis

Interventions

DRUG

AC-170 0.05%

1 drop in each eye at 3 separate times during a 21 day period

DRUG

AC-170 0.1%

1 drop in each eye at 3 separate times during a 21 day period

DRUG

AC-170 0.24%

1 drop in each eye at 3 separate times during a 21 day period

DRUG

AC-170 0%

1 drop in each eye at 3 separate times during a 21 day period

Trial Locations (1)

Ora, Inc., Andover